Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 195.00p 190.00p 200.00p 195.00p 195.00p 195.00p 53,165.00 07:37:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.4 -20.1 -28.8 - 119.89

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp Forums and Chat

Date Time Title Posts
27/2/201717:11Summit - Climbing to new heights22,192.00
10/3/201615:43Professor Mark Wilcox Interview on C Diff1.00
23/5/201409:49Summit Corporation749.00
22/5/201416:46Summit Corporation plc37.00
21/5/201413:59Summit plc - Combating 'C. difficile' and lots more14,162.00

Add a New Thread

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 195p.
Summit Corporation has a 4 week average price of 187.13p and a 12 week average price of 169.72p.
The 1 year high share price is 260p while the 1 year low share price is currently 82.50p.
There are currently 61,484,452 shares in issue and the average daily traded volume is 43,271 shares. The market capitalisation of Summit Corporation is £119,894,681.40.
freemoney1: Hi H-M, Great work form you and Waterloo. As Waterloo points out any deal will give upfronts and milestones which will more than offset any further development and set-up costs. So to simplify calculation I just use the predicted peak sales and assume a 20% royalty. The Crystal Ball Calculator puts out values between £11-£16 per share ...depending which way the wind is blowing :-) So my point is with the share price below £2 it would seem a no brainer to invest at this level knowing the share is underpinned by that value in 3-4 years time and the 'free' gamble of the multi billion $ DMD programme hitting success... which could be worth £100's per share IMHO without further dilution. It's all looking very exciting... it'd be nice to see the FDX results and a deal soon to boost the share price to where it should be.... but then again if it stays low we can move more shares to ISA in April... win win :-) GLA
hugus maximus: I am no accountant but would expect a more modest $500 million per year C Diff market (that figure clearly dependent on whatever the drug's market price is) ... my stab at expectations over the next few months for C Diff:- As a consequence of a 3rd party major Pharma involvement with C Diff, might Summit realistically be looking for a downpayment of say $75 - 100 million and up to a 30% royalty? Therefore the initial C Diff drug effect on share price stabilising at around £3 ... until further income is eventually generated by sales which would then enhance the share price greatly? (The above having no bearing whatsoever on DMD share price enhancement which is obviously the big prize)
chrisatrdg: Per Free-Money from the other board this morning - any takers? 'Ridinilazole value per share ? This would seem to be a fundamental question for new investors now or LTH looking to top up at this price. We've recently been told the European and US agency are supportive of Summit Phase 3 programme and Ridnilazoles route to market. Knowing RDZ can be used as first and second line treatment and the market is worth about $1bln in annual sales we should be able to give the drug a share price value for 2021. If you can calculate that value and buy below that price then the gamble on the DMD programme is a free gamble as far as I see it. So what is the value of RDZ with Summit's roughly 62milion shares and assume it will be partnered giving Summit 20% royalties per year ? Lets assume for this exercise that since P3 is just a replica of the very successful P2 trial, only bigger, then we do not need to account for risk of success in my opinion. It’s just a matter of time to market now. I've worked out what I think but I'd be interested to see what others come up with and how you arrive at that value? Something to do while we wait and could be very interesting for those looking to invest.... in a 'free ride for shareholders' - Glyn AGM comment :-)'
freemoney1: Good share price reaction on both sides of the pond. But I see there is still a massive valuation difference between Sarepta and Summit. Market capitalisations : Summit : $110.53m Sarepta : $2,149.57m Once Ezutromid and Utrophin upregulation is proven (Q2/3) we should at least equal Sarepta in valuation but many would argue that since we can treat 100% of the population and we retain the most valuable market (US) we should exceed Sarepta's valuation. That's some upside!!!! We also have the second programme, C.Diff, which is due to deliver value to shareholders in the near term. Hopefully new investors with deep pockets are realising all this and our share price will continue to correct. GLA
hugus maximus: IMO Sarpeta share interest is a consequence of them finally rolling out eteplirsen after a slow start and the announcement to that effect (a couple of days ago) brings their FDA promise toward some sort of actual fruition. Hence Sarepta's slow drop in share price in the months after the FDA approval date, was due to expectations not being met quickly enough (both in demand and supply). There were many reports of difficulties until this weeks announcement that things had turned around. I wonder if their pipe line Exon 51 is too much a part of the distant future to produce todays share price effect ... although will perhaps have endorsed their position slightly? Maybe Summit are riding on Sarepta's coat tails and the market has turned from hot to cold to warm again about wariness of DMD market in general? Let's hope that the improved eteplirsen pipeline holds for a while, allowing Summit to come in with some serious guns blazing and their shares being bought on their own terms. IMO If Summit can prove with their empirical full comprehensive clinical testing that Ezutromid stands up to the plate (as opposed to the more subjective eteplisen research work which still casts elements of doubt), the DMD market will finally and categorically be banging at their door. EDIT - unless I've missed something majorly significant announced at the San Fran Health Conference which made Summit's shares move up independently last night?
hugus maximus: All IMHO ... Another view about valuations of similar companies and share price can be expressed in the valuation of SAREPTA, a DMD research company that was once in a very similar situation SUMMIT. When it's DMD drug showed promising results during P2 trials it's share price rocketed from under $1 in 2012 to over $50 in 2013 (a drug which only every had a potential cure rate of ~13% of DMD boys) The probable announcement from the FDA next week that Sarepta's failed DMD drug will be stripped of its permission to proceed, will see it's share price fall significantly and find the market looking for the next potential cure. The fact that Summit has so far been seen as a two bit small UK company in a chauvinistic american market place, has been the reason for the share slide. Aside from any value that Summit's C Diff drug has a result of its successful P2 trial results and potential deal with a large pharma, the potential DMD earnings will see the share price reach many multiples of where it is now over the coming months.
hugus maximus: Fascinating review of "things" buywell3! I'm going to save your note with the great hope that I can bring it back to haunt you one day. In addition to that, I will haunt you with my own predictions: 1. There will be a C Diff drug sale / licensing deal over the next 3-6 months. Glyn Edwards will most likely be presenting final reports next week in response to initial P2 data top line info. When as good as anticipated, that will make SMT19969 the "best drug in show" for treating C Diff by some large margin. Henceforth with a deal, we will have a financial injection anywhere between $60m-$150 million ... that alone should be responsible for doubling the share price before September. 2. The sadly less successful major DMD companies (Serepeta etc) all saw major share price upward movement during P2 trial ... their share price increased many multiples well before final P2 results. When we start to report results as the open trial progresses, that will add in major increments to an upward share price. The next 12 months will see a huge upward move in share price So there we are .. if you have invested here buywell, I'm sure you'll prefer my version of events! GLA HM
hugus maximus: SHOULD WE BE CONCERNED? Following Waterloo's remarks above: It's all well and good that we are funding a company that is all about "the science" but one wonders if Summit do deliver great results with the DMD tests, what will this actually do to the value of a company that has little profile and track record? Many of us have held a view that the science is all that's important, but given the company's success with C Diff P2 trials, (albeit waiting for final detailed data) and the tepid market reaction on the days following results were announced last year, one does wonder if Summit need to take a serious look at the lack of attention we still seem to have in the market place? I am not suggesting for a minute that we pay some ridiculous PR company a fortune to hype a profile .. but surely by now we should at least be getting name checks in the sort of Bloomberg article Waterloo points up above? I do worry that lack of profile will mean we're taken less seriously in the event of DMD success. The share price after SMT19699 has been proven to be at the very least "AN IMPROVEMENT ON CURENT STANDARD OF CARE IN THE TREATMENT OF C DIFF" is abysmal. Released into the Public Domain in 2015 are test results that state, together with an FDA Fast Track approval, we at least have a drug that is more effective than the best known current drug treatment for C Diff ... and Summit is still such a little known company with a share price that's on the floor. If DMD is a success, will Summit coming from nowhere help to enhance the companies value? Or does something have to be done to shine a wee light here? I am beginning to question this? Not long ago, a company's profile would have had little to do with it's eventual share price after a successful drug discovery. I am beginning to question whether this has changed? After being a significant share holder for 3 years, I can't say that I feel very comfortable about this side of "things". Is there more that Summit should be doing to change this ... or is this an irrelevance?
football: Summit Corporation – Follow Jim Mellon and buy at 115p - In August's edition of an obscure online publication, Jim Mellon tipped Summit PLC (SUMM) to do great things. Mr Mellon's track record and judgement in picking winners on AIM is second to none. Summit is a company Ben used to follow quite closely. The science it is developing is truly marvellous, even if its path has been a horribly bumpy ride lower for long term shareholders. No one is going to pretend that this has been a good stock hold over a long period of time, but that is in the past. Now priced at 115p (last seen) this could be a good opportunity to buy into a business, which has previously offered so much incredible potential. Ben last covered Summit, immediately after February's placement. He wasn't exactly complimentary about the price of this fundraising, but did point out that Summit was back on the watchlist. Admittedly we are very glad we didn't buy into it, as the share price has continued to fall, after recovering briefly. However, our reasons for considering this stock remain broadly the same. Since his appointment in the spring of 2012, CEO Glynn Edwards appears to have done a much better job in moving the company forward than his academic predecessors. Take a stroll through Summit's historical RNSs and compare the speed, content and tone of announcements before he joined the company with those since he took the helm and you should quickly see what I mean. Admittedly Summit's share price doesn't now reflect much of this development, but this could be what sets extremely savvy investors like Jim Mellon apart from the rest of the herd. Tom had a friendly exchange of emails with Jim today and that reinforces our view of what a good and clever man he is. On June 3rd this year, Summit announced a dreaded share consolidation, which was subsequently approved. The reputation of consolidations is not good among private investors and they are associated with share price pain. In the case of Summit, so far this feeling has been borne out, but now the company has only 41million shares in issue, this could be very positive if good news is around the corner. The tightly held nature of this stock could mean market makers struggle to satisfy demand if buyers are tempted back in their numbers. The consolidation itself was 20/1 so in old money Summit is worth 5.75p a share. This is a 12% discount to February's already discounted placement. Again it is easy to sympathise with stale holders who gripe about this, but the market has no memory. Reading between the lines and Mr Mellon's illusive reference to Summit has really caught my eye. He said "I am a fan of Summit plc, which is well financed and has two drugs in development". OK so this quote isn't much to go on, but when you consider Mr Mellon is a non-exec of Summit's and also holds 5.95% of the company through his trust Galloway Limited, perhaps he's just tipped us a little wink that he knows something pleasing is brewing in the background. You might think we are adding 2 + 2 and coming up with 117. We can take that on the chin, but even if we've misinterpreted Mr Mellon's comments, the rationale for buying into Summit now looks compelling. Http://
theunluckyone: Apologies - I have not looked in since early this morning as been researching another share but here is my research findings for those that have not filtered me !!!! Over the last few days I have done a LOT of research on Antisoma and bearing in mind our shared hatred of dodgy dealings I thought you may be interested in some of my findings.Summits CFO Spencer was first on the scene at Antisoma in 1996 followed by Price in 1997 and Edwards was installed as CEO in March 1998.Within days he had been awarded the first batch of share options of course at a huge discount to the prevailing market price.In fact he was awarded - and Spencer - so many cheap options that in some years THREE separate batches were issued.Over the subsequent 7 years he was granted in excess of SEVEN MILLION share options at prices of up to 211.9p so we are not talking about insignificant amounts of money.Trouble is with the constantly destroying of shareholder value that by the time the options could be utilised the shares were just as cheap in the market so he or his advisers devised the Executive Incentive Plan.These were identical to Share Options other than these were all granted at an excercise price of ONE PENNY per share.Over the next five years he was granted awards over SEVEN MILLION shares.If this was not a big enough of a reward - some might say greedy already - a new " Matching Shares " plan was put into effect under which for any shares bought by three directors ( Edwards and Spencer included ) and held for five years then they were entitled to buy 150% of their original purchase at the end of that period at a price of ONE PENNY per share. There were conditions and targets set but you can guess how much of a burden it was to achieve them !!!!! During his tenure at Antisoma Edwards was able to acquire virtually THREE MILLION shares at ONE PENNY per share and Spencer over a minimum of 200000 shares at the same price.Incidentally over the last 7 years that Edwards was CEO he presided over losses of £134.1 MILLION and burnt £163.4 MILLION in cash !! His salary over that seven years was nearly FOUR MILLION POUNDS while Spencer earned a paltry £1.63 MILLION POUNDS.It may well be a coincidence but at the height of its extravagance and generosity to Edwards and Spencer the non executive Head of Remuneration resigned without warning or explanation - a step no one takes without considerable forethought. When the need for cash became too great a heavily diluting oversubscribed Institutional placing was arranged and the same names appeared on the share register as having received shares and over the following few weeks those shares were sold into the market and those Institutions disappeared off the share register.Then the same thing happened after the next placing with the same names often appearing - Morgan Stanley,Goldman Sachs,Legal and General,Equitable Life,UBS,and their two main backers Leventis and Orbimed all did exactly the same thing.Very similar to what happened in Summits last placing and I have requested to see the Share Register of Summit to see if these names appear but Summit has up to now turned a deaf ear to my request which heightens my suspicious mind and makes me double my determination to see this Register !!! As another poster on here repeatedly states,Edwards could have done Summits last placement of shares at 9p but he went to Singers and did it for a disgracefully lower price.After his experience at Antisoma he should have realised that the shares would be just churned and a suspicious person might wonder what his motivation would have been. Anyway back to our mirror company Antisoma. Summit is hinting that a NASDAQ listing is a possibility and the same thing happened in Antisoma during April 2005 and actually achieved an ADR listing in December 2005 as a stepping stone to a full listing at a later stage. This may also be familiar but every other week Edwards was in the USA giving presentations here there and everywhere.Spencer left the company just before the end of 2008 for non disclosed reasons but business continued in its usual manner although,as with Summit ,the company was only able to keep the money flowing due to successful scientific results from their MAIN anti cancer drug that did actually go into Phase 3 trials before disaster struck - for some reason their drug did not meet its primary endpoint and was discontinued.The company basically put itself up for sale and Edwards looked for the exit rather than hang around and ensure the future of a company that he had had enjoyed staggering amounts of money from for 13 years.Not only did he desert a sinking ship but he actually kicked another bloody great hole in its already severely weakened hull by walking away with a monster compensation package that helped result in the sacking of all of their other staff to stave off bankruptcy.You can see what would happen if Summits prospects failed - not that that is going to happen !!!!! Edwards left Antisoma on the 28th of February 2011 followed 2 days later by Price who had seen his salary more than double under Edwards.And he was working at Summit. Just as a very interesting aside to this situation the ultimate saviour of Antisoma was ORA ( Guernsey ) which is ultimately owned by Richard Griffiths who of course is one of the millionaires that has a stake in Summit.Now I wonder who could have told Griffiths about Antisoma !!!!! As I have stated on the BB I believe that Summits share price is being manipulated downwards and that a low ball takeover offer will be made by a group of individuals maybe for as low as £2.00 per share using our manipulated share price to prove how good their offer is.If you do as much in depth analysis as I do you will notice how many times the names of Keith,Griffiths and Henderson Global come up as significant shareholders in the same company although as far as I know only 2 of these currently have a large enough interest to have to be disclosed. I did not trust Edwards before the AGM - I was the only person to vote against his re appointment as a director - but after his performance at the meeting I gave him the benefit of the doubt although that did not last long.The RNS s the week after the meeting were exactly the opposite to information he gave at the AGM which I think is disgraceful and reaffirmed by belief that he could not be trusted. People keep rubbishing my idea about a low ball offer but why would any sane person sell a share for £1.20 today if it is going to be worth multiples of that figure within months ?
Summit Corp share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170227 18:15:05